10-22-15

Page 1

The Pitt News

Game of Thrones and Political Theory page 6

T h e i n d e p e n d e n t st ude nt ne w spap e r of t he University of Pittsburgh

ADOPTING A TESTING TREATMENT NARRATIVE Pitt researchers and physicians study different drugs to treat a less common form of breast cancer. | by Annemarie Carr | Staff Writer

Cristina McCormack Staff Writer

Adopting a child is meant to create a family, but narratives show that it can also isolate the individual. Four panelists specializing in adoption studies participated in an English departmentand Humanities Center-sponsored panel discussion called “Adoption and Narratives of the Human.” The speakers discussed why both literary and non-literary narratives of adoption — the way people write, talk and study adoption experiences — define America’s dialogue on adoption. The event, held on Wednesday, Oct. 21, from 3:30 to 5 p.m., was a part of Pitt’s Year of the Humanities. About 20 Pitt students and community members gathered on the sixth floor of the Cathedral of Learning to hear four narratives and engage in a question and answer session, organized by Marianne Novy, a Pitt English professor. According to the State Department’s 2014 Annual Report on Intercountry Adoption, there were a total of 6,441 international adoptions in 2014. For the past four years, China has been the leading adoption state and country. In 2013, there were 7,092 adoptions from China and 138 from South Korea. Panelist Margaret Homans, a professor See Humanities on page 3

When it comes to treating breast cancer, Pitt researchers say there won’t be a one size fits all solution. Physicians at Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute (UPCI) are testing the effects the three most common anti-estrogen treatments for breast cancer have on invasive lobular carcinoma. According to the physician researchers, ILC is a less common form of breast cancer than the more well-known and understood form of breast cancer, invasive ductal carcinoma. According to the American Cancer Society, about 180,000 new cases of invasive breast cancer have been diagnosed in the United States this year. Dr. Rachel Jankowitz, the trial’s principal investigator, said ILC affects about 5 percent to 15 percent of these breast cancer patients, and physicians often treat ILC no differently when it comes to treatment. “Currently, there is a one-size-fitsall approach in how we treat patients

with invasive lobular breast cancer and invasive ductal carcinoma,” Jankowitz said in a UPMC release

Physician researchers like Sheffi Oesterreich, a professor of pharmacology and chemical biology at Pitt, launched the trial that began two to three weeks ago at Magee and the University of Pittsburgh Cancer Institute. Oesterreich expects the trial will enroll 150 participants, which the researchers will randomly divide into three equal therapeutic groups. Each group will receive one of three common anti-estrogen drugs, which the participants will take during a 21-day period before surgery. The drugs each work differently in the body: Tamoxifen is an estrogen receptor modulator, Anastrozole inhibits the enzyme that synthesizes estrogen and Fulvestrant is a complete estrogen receptor blocker. “Our trial will examine how ILC tumor tissue responds to the current standards of care — treatment with either Tamoxifen or Anastrozole, as compared to Fulvestrant, a drug currently approved only to treat advanced breast cancer,” Oesterreich said. After the research, Jankowitz said she See Breast Cancer on page 2

Illustration by Terry Tan


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.